Key Findings
The FDA has approved Bayer’s asundexian (marketed as Sunharbo), an oral factor XIa (FXIa) inhibitor, to reduce the risk of recurrent stroke in adults following a noncardioembolic ischemic stroke or high-risk transient ischemic attack (TIA). The approval is based on the phase 3 OCEANIC-STROKE trial, which demonstrated that asundexian 50 mg once daily, used in combination with antiplatelet therapy, significantly reduced the risk of ischemic stroke by 26% over a median treatment period of 14.2 months.
Technical Details
The double-blind OCEANIC-STROKE trial enrolled 12,327 patients (asundexian, n = 6162; placebo, n = 6165) randomized within 72 hours of a qualifying event. Eligible patients had an NIHSS score of 15 or less and presented with at least one of the following: a nonlacunar infarct on imaging, a history of atherosclerosis, or atherosclerotic plaque on cerebrovascular imaging.
- Primary Efficacy: Ischemic stroke occurred in 6.2% of the asundexian group vs 8.4% in the placebo group (HR 0.74; P <.001). Ischemic or hemorrhagic stroke occurred in 6.6% vs 8.8% (HR 0.74; P <.001).
- Composite Outcomes: Cardiovascular death, myocardial infarction, or stroke occurred in 9.2% vs 11.1% (HR 0.83; P <.001). All-cause death, MI, or stroke occurred in 10.5% vs 12.3% (HR 0.85; P = .003).
- Safety: ISTH-defined major bleeding occurred in 1.9% of asundexian patients vs 1.7% for placebo (HR 1.10; P = .46). Serious adverse events were reported in 19.2% vs 19.5%.
Background & Context
Non-cardioembolic ischemic strokes represent approximately 45% of the 12 million global annual strokes, with roughly 1 in 10 patients experiencing recurrence within one year despite guideline-recommended therapy. The 50-mg dose used in this trial was informed by the phase 2b PACIFIC-STROKE trial, which showed a signal for fewer symptomatic strokes, particularly in patients with atherosclerosis.
Significance & Outlook
Asundexian is the first FXIa inhibitor approved for secondary stroke prevention. Its use is limited to noncardioembolic stroke/high-risk TIA populations; it is not approved for atrial fibrillation and is not recommended for patients with moderate or severe hepatic impairment. Clinical labeling advises avoiding combined P-gp/strong CYP3A4 inducers and withholding the drug for at least 24 hours before elective procedures or after thrombolysis.
Source: https://www.neurologylive.com/view/fda-approves-asundexian-treatment-secondary-stroke-prevention
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime



